Q3 2017 EPS Estimates for CryoLife, Inc. Decreased by First Analysis (NYSE:CRY)

CryoLife, Inc. (NYSE:CRY) – Analysts at First Analysis decreased their Q3 2017 earnings per share estimates for CryoLife in a report issued on Monday. First Analysis analyst now forecasts that the medical equipment provider will earn $0.06 per share for the quarter, down from their previous forecast of $0.11. First Analysis also issued estimates for CryoLife’s Q4 2017 earnings at $0.10 EPS and Q2 2018 earnings at $0.10 EPS.

CryoLife (NYSE:CRY) last issued its quarterly earnings results on Monday, July 24th. The medical equipment provider reported $0.12 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.10 by $0.02. CryoLife had a net margin of 6.16% and a return on equity of 7.41%. The business had revenue of $47.80 million for the quarter, compared to analysts’ expectations of $47.02 million. During the same quarter last year, the company posted $0.13 EPS. The company’s revenue was up 1.5% compared to the same quarter last year.

TRADEMARK VIOLATION NOTICE: “Q3 2017 EPS Estimates for CryoLife, Inc. Decreased by First Analysis (NYSE:CRY)” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://www.com-unik.info/2017/08/12/q3-2017-eps-estimates-for-cryolife-inc-decreased-by-first-analysis-nysecry-updated.html.

Other analysts have also issued research reports about the stock. BidaskClub lowered shares of CryoLife from a “hold” rating to a “sell” rating in a research note on Tuesday. Northland Securities reiterated a “buy” rating and issued a $23.50 price objective on shares of CryoLife in a research note on Friday, April 28th. Finally, Zacks Investment Research upgraded shares of CryoLife from a “hold” rating to a “buy” rating and set a $21.00 price objective on the stock in a research note on Thursday, June 8th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $22.00.

CryoLife (NYSE:CRY) opened at 18.65 on Tuesday. The company’s 50 day moving average is $19.35 and its 200-day moving average is $17.95. The stock has a market cap of $623.77 million, a PE ratio of 56.52 and a beta of 0.99. CryoLife has a 1-year low of $13.88 and a 1-year high of $20.30.

In related news, VP Amy Horton sold 9,577 shares of the firm’s stock in a transaction on Tuesday, June 27th. The shares were sold at an average price of $20.00, for a total transaction of $191,540.00. Following the sale, the vice president now owns 112,282 shares in the company, valued at $2,245,640. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 6.00% of the stock is currently owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in CRY. Trexquant Investment LP purchased a new stake in CryoLife during the second quarter valued at approximately $291,000. Essex Investment Management Co. LLC raised its stake in CryoLife by 21.9% in the second quarter. Essex Investment Management Co. LLC now owns 117,849 shares of the medical equipment provider’s stock valued at $2,351,000 after buying an additional 21,206 shares in the last quarter. Texas Permanent School Fund raised its stake in CryoLife by 1.7% in the second quarter. Texas Permanent School Fund now owns 19,913 shares of the medical equipment provider’s stock valued at $397,000 after buying an additional 333 shares in the last quarter. Municipal Employees Retirement System of Michigan raised its stake in CryoLife by 3.7% in the second quarter. Municipal Employees Retirement System of Michigan now owns 6,380 shares of the medical equipment provider’s stock valued at $127,000 after buying an additional 230 shares in the last quarter. Finally, Thomson Horstmann & Bryant Inc. purchased a new stake in CryoLife during the second quarter valued at approximately $1,873,000. Institutional investors own 68.15% of the company’s stock.

CryoLife Company Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

What are top analysts saying about CryoLife Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CryoLife Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit